Tyrosine kinase inhibitors (TKIs) have revolutionized cancer treatment by offering targeted therapies that disrupt specific cellular signaling pathways critical for tumor growth and survival. These small molecules selectively inhibit tyrosine kinases, enzymes that transfer phosphate groups from ATP to tyrosine residues on proteins. TKIs represent a milestone in personalized oncology, showing...